[Other] Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.

Hipocraticpride Post time 1 hour(s) ago | Show all posts |Read mode

This post will be closed automatically in 2026-07-31 07:35

Reward10points

Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, López C, Sung M, Mody K, Ohtsuka T, Tamai T, Bennett L, Meier G, Breder V. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Lancet Gastroenterol Hepatol. 2021 Aug;6(8):649-658.
doi: 10.1016/S2468-1253(21)00110-2. Epub 2021 Jun 2.
PMID: 34087115.

You can support us by donating, we would be very grateful.

Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

Hipocraticpride Lv.2

Junior Member

post
reply
points
40

[Other] Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Copy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.